Fluoro-Taxoid Anticancer Agents

Fluorine in Medicinal Chemistry and Chemical Biology

Volumn , Issue , 2009, Pages 117-139

  Pepe, Antonella ^a   Kuznetsova, Larisa ^b   Sun, Liang ^c   Ojima, Iwao ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Fluoro taxoid anticancer agents; Importance of fluorine in bioorganic and medicinal chemistry; Paclitaxel (Taxol ) and its semisynthetic analogue docetaxel; Paclitaxel, taxoids, and second generation taxoids; Possible bioactive conformations of fluoro taxoids; Second generation Taxoids and C seco taxoids with strategic incorporation of fluorine; Synthesis and biological evaluation of C 2 (3 Fluorobenzoyl) C seco taxoids; Synthesis and biological evaluation of C 3 difluorovinyl taxoids

Indexed keywords

EID: 79955573332     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444312096.ch5     Document Type: Chapter

References (69)

1. Begue, J.-P. and Bonnet-Delpon, D. (2006) Recent advances (1995-2005) in fluorinated pharmaceuticals based on natural products. Journal of Fluorine Chemistry, 127, 992-1012.
2. Isanbor, C. and O'Hagan, D. (2006) Fluorine in medicinal chemistry: A review of anti-cancer agents. Journal of Fluorine Chemistry, 127, 303-319.
3. Cottet, F., Marull, M., Lefebvre, O. and Schlosser, M. (2003) Recommendable routes to trifluoromethyl-substituted pyridine-and quinolinecarboxylic acids., European Journal of Organic Chemistry, 1559-1568.
4. Kirk, K. L. (2006) Fluorine in medicinal chemistry: Recent therapeutic applications of fluorinated small molecules Journal of Fluorine Chemistry, 127, 1013-1029.
5. Müller, K., Faeh, C. and Diederich, F. (2007) Fluorine in Pharmaceuticals: Looking beyond intuition. Science, 317, 1881-1886.
6. O'Hagan, D., Schaffrath, C., Cobb, S. L., et al. (2002) Biochemistry: Biosynthesis of an organofluorine molecule. Nature, 416, 279-279.
7. Martino, R., Malet-Martino, M. and Gilard, V. (2000) Fluorine nuclear magnetic resonance, a privileged tool for metabolic studies of fluoropyrimidine drugs. Current Drug Metabolism, 1, 271-303.
8. Rowinsky, E. K. (1997) The development and clinical utility of the taxane class of antimicro-tubule chemotherapy agents. Annual Review of Medicine, 48, 353-374.
9. FDA. (2004) Drug Approvals. http://www.fda.gov/cder/approval7t.htm.
10. Schiff, P. B., Fant, J. and Horwitz, S. B. (1979) Promotion of microtubule assembly in vitro by taxol. Nature, 277, 665-667.
11. Jordan, M. A., Toso, R. J. and Wilson, L. (1993) Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentration. Proceedings of the National Academy of Sciences of the U S A, 90, 9552-9556.
12. Georg, G. I., Chen, T. T., Ojima, I. and Vyas, D. M. (1995) Taxane Anticancer Agents: Basic Science and Current Status, American Chemical Society, Washington, D. C.
13. Suffness, M. (1995) Taxol, Science and Applications, CRC Press, New York.
14. Bristol-Myers, S. (2003) Taxol (paclitaxel) Injection. http://packageinserts.bms.com/pi/pi_taxol.pdf.
15. Gottesman, M. M., Fojo, T. and Bates, S. E. (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer, 2, 48-58.
16. Ojima, I., Slater, J. C., Michaud, E., et al. (1996) Syntheses and structure-activity relationships of the second generation antitumor taxoids. Exceptional activity against drug-resistant cancer cells. Journal of Medicinal Chemistry, 39, 3889-3896.
17. Ojima, I., Wang, T., Miller, et al. (1999) Synthesis and structure-activity relationships of new second-generation taxoids. Bioorganic & Medicinal Chemistry Letters, 9, 3423-3428.
18. Ojima, I., Kuduk, S. D., Slater, J. C., et al. (1996) Syntheses of new fluorine-containing taxoids by means of ß-lactam synthon method. Tetrahedron, 52, 209-24.
19. Ojima, I., Kuduk, S. D., Slater, J. C., et al. (1996) Syntheses, biological activity, and conformational analysis of fluorine-containing taxoids, in Biomedical Frontiers of Fluorine Chemistry, ACS Symposium Series 639 (eds I. Ojima, J. R. McCarthy, J. T. and Welch.), American Chemical Society, Washington, D.C., pp. 228-243.
20. Ojima, I., Slater, J. C., Pera, P., et al. (1997) Synthesis and biological activity of novel 3'-trifluoromethyl taxoids. Bioorganic & Medicinal Chemistry Letters, 7, 133-138.
21. Ojima, I., Inoue, T., Slater, J. C., et al. (1999) Synthesis of enantiopure F-containing taxoids and their use as anticancer agents as well as probes for biomedical problems, in Asymmetric Fluoroorganic Chemistry: Synthesis, Application, and Future Directions, ACS Symposium Series 746 (ed. P. V. Ramachandran), American Chemical Society, Washington, D. C, pp 158-181.
22. Sullivan, K. F. (1988) Structure and utilization of tubulin isotypes. Annual Review of Cell Biology, 4, 687-716.
23. Banerjee, A., Roach, M. C., Trcka, P. and Luduena, R. F. (1992) Preparation of a monoclonal antibody specific for the class IV isotype of beta-tubulin. Purification and assembly of alpha beta II, alpha beta III, and alpha beta IV tubulin dimers from bovine brain. Journal of Biological Chemistry, 267, 5625-5630.
24. Panda, D., Miller, H. P., Banerjee, A., et al. (1994) Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proceedings of the National Academy of Sciences of the USA, 91, 11358-11362.
25. Kavallaris, M., Kuo, D. Y. S., Burkhart, C. A., et al. (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. Journal of Clinical Investigation, 100, 1282-1293.
26. Sharma, J. and Luduena, R. F. (1994) Use of N,N (-polymethylenebis(iodoacetamide) derivatives as probes for the detection of conformational differences in tubulin isotypes. Journal of Protein Chemistry, 13, 165-76.
27. Schwarz, P. M., Liggins, J. R. and Luduena, R. F. (1998) Beta-tubulin isotypes purified from bovine brain have different relative stabilities. Biochemistry, 37, 4687-4692.
28. Derry, W. B., Wilson, L., Khan, I. A., et al. (1997) Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified ß-tubulin isotypes. Biochemistry, 36, 3554-3562.
29. Ferlini, C., Raspaglio, G., Mozzetti, S., et al. (2005) The seco-taxane IDN5390 is able to target class III ß-tubulin and to overcome paclitaxel resistance. Cancer Research, 65, 2397-2405.
30. Haber, M., Burkhart, C. A., Regl, D. L., et al. (1995) Altered expression of Mbeta2, the class ii beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. Journal of Biological Chemistry, 270, 31269-31275.
31. Kavallaris, M. (1999) Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. British Journal of Cancer, 80, 1020-1025.
32. Ojima, I. (1995) Recent advances in ß-lactam synthon method. Accounts of Chemical Research, 28, 383-389.
33. Ojima, I. (1995) Asymmetric syntheses by means of ß-lactam synthon method, in Advances in Asymmetric Synthesis (ed A. Hassner), JAI Press, Greenwich, pp 95-146.
34. Kuznetsova, L., Ungureanu, I. M., Pepe, A., et al. (2004) Trifluoromethyl-and difluoromethyl-ß-lactams as useful building blocks for the synthesis of fluorinated amino acids, dipeptides, and fluoro-taxoids. Journal of Fluorine Chemistry 125, 487-500.
35. Lin, S., Geng, X., Qu, C., et al. (2000) Synthesis of highly potent second-generation taxoids through effective kinetic resolution coupling of racemic ß-lactams with baccatins. Chirality 12, 431-141.
36. Ojima, I., Lin, S., Slater, J. C., et al. (2000) Syntheses and biological activity of C-3'-difluoromethyl-taxoids. Bioorganic & Medicinal Chemistry, 8, 1619-1628.
37. Skehan, P., Storeng, R., Scudiero, D., et al. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. Journal of the National Cancer Institute, 82, 1107-1112.
38. Huzil, J. T., Luduena, R. F. and Tuszynski, J. (2006) Comparative modelling of human ß tubulin isotypes and implications for drug binding. Nanotechnology 17, S90-S100.
39. Ojima, I., Slater, J. S., Kuduk, S. D., et al. (1997) Syntheses and structure-activity relationships of taxoids derived from 14ß-hydroxy-10-deacetylbaccatin III. Journal of Medicinal Chemistry, 40, 267-278.
40. Ojima, I., Sun, C. M. and Park, Y. H. (1994) New and efficient coupling method for the synthesis of peptides bearing norstatine residue and their analogs. Journal of Organic Chemistry, 59, 1249-1250.
41. Appendino, G., Danieli, B., Jakupovic, J., et al. (1997) Synthesis and evaluation of C-seco paclitaxel analogues. Tetrahedron Letters, 38, 4273-1276.
42. Appendino, G., Noncovich, A., Bettoni, P., et al. (2003) The reductive fragmentation of 7) hydroxy-9,10-dioxotaxoids. European Journal of Organic Chemistry, 4422-1431.
43. Gut, I., Ojima, I., Vaclavikova, R., et al. (2006) Metabolism of new generation taxanes in human, pig, minipig and rat liver microsomes. Xenobiotica 36, 772-792.
44. Vuilhorgne, M., Gaillard, C., Sanderlink, G. J., et al. (1995) Metabolism of Taxoid Drugs, in Taxane Anticancer Agents: Basic Science and Current Status, ACS Symp. Ser. 583 (eds G. I. Georg, T. T. Chen, I. Ojima and D. M. Vyas), American Chemical Society, Washington, D. C., pp 98-110.
45. Ojima, I., Sun, C. M., Zucco, M., et al. (1993) A highly efficientroute to taxotère by the ß-lactam synthon method. Tetrahedron Letters, 34, 4149-4152.
46. Ojima, I., Habus, I., Zhao, M., et al. (1992) New and efficient approaches to the semisynthesis of taxol and its C-13 side-chain analogs by means of betalactam synthon method. Tetrahedron, 48, 6985-7012.
47. Ojima, I., Kuduk, S. D. and Chakravarty, S. (1998) Recent advances in the medicinal chemistry of taxoid anticancer agents, in Advanced Medicinal Chemistry (eds B. E. Maryanoff and A. B. Reitz,), JAI Press, Greenwich, CT, pp 69-124.
48. Ojima, I., Kuduk, S. D., Chakravarty, S., et al. (1997) A novel approach to the study of solution structures and dynamic behavior of paclitaxel and docetaxel using fluorine-containing analogs as probes. Journal of the American Chemical Society, 119, 5519-5527.
49. Li, Y., Poliks, B., Cegelski, L., et al. (2000) Conformation of Microtubule-Bound Paclitaxel Determined by Fluorescence Spectroscopy and REDOR NMR. Biochemistry, 39, 281-291.
50. Geney, R., Sun, L., Pera, P., et al. (2005) Use of the tubulin bound paclitaxel conformation for structure-based rational drug design, Chemistry & Biology, 12, 339-348.
51. Rao, S., He, L., Chakravarty, S., et al. (1999) Characterization of the taxol binding site on the microtubule. Identification of Arg282 in ß tubulin as the site of photoincorporation of a 7 -benzophenone analogue of taxol. Journal of Biological Chemistry, 274, 37990-37994.
52. Nogales, E., Wolf, S. G. and Downing, K. H. (1998) Structure of the aß tubulin dimer by electron crystallography. Nature 391, 199-203.
53. Paik, Y., Yang, C., Metaferia, B., et al. (2007) Rotational-echo double-resonance NMR distance measurements for the tubulin-bound paclitaxel conformation. Journal of the American Chemical Society, 129, 361-370.
54. Lowe, J., Li, H., Downing, K. H. and Nogales, E. (2001) Refined structure of alpha beta-tubulin at 3.5 A resolution. Journal of Molecular Biology, 313, 1045-1057.
55. Sun, L., Geng, X., Geney, R., et al. (2008) Design, synthesis and biological evaluation of novel C14-C3'Bz N-linked macrocyclic taxoids, Journal of Organic Chemistry, 73, 9584-9593.
56. Ojima, I., Kuznetsova, L. V. and Sun, L. (2007) Organofluorine chemistry at the biomedical interface-a case study on fluoro-taxoid anticancer agents, in Current Fluoroorganic Chemistry. New Synthetic Directions, Technologies, Materials and Biological Applications (eds V. Solo-shonok, K. Mikami, T. Yamazaki, J.T. Welch and J. Honek), American Chemical Society/Oxford University Press, Washington, D.C., pp 288-304.
57. Chen, J., Jaracz, S., Zhao, X., et al. (2005) Antibody-based toxin conjugates for cancer therapy. Expert Opinion in Drug Delivery, 2, 873-890.
58. Jaracz, S., Chen, J., Kuznetsova, L. V. and Ojima, I. (2005) Recent advances in tumor-targeting anticancer drug conjugates. Bioorganic & Medicinal Chemistry, 13, 5043-5054.
59. Chari, R. V. J. (1998) Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Advanced Drug Delivery Reviews, 31, 89-104.
60. Liu, C., Tadayoni, B. M., Bourret, L. A., et al. (1996) Eradication of large colon tumor xeno-grafts by targeted delivery of maytansinoids. Proceedings of the National Academy of Sciences of the U S A, 93, 8618-8623.
61. Hamann, P. R., Hinman, L. M., Hollander, I., et al. (2002) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chemistry, 13, 47-58.
62. Lam, L., Lam, C., Li, W. and Cao, Y. (2003) Recent advances in drug-antibody immunoconju-gates for the treatment of cancer. Drugs of the Future, 28, 905-910.
63. Saleh, M. N., LoBuglio, A. F. and Trail, P. A. (1998) Monoclonal antibody-based immunocon-jugate therapy of cancer: studies with BR96 -doxorubicin. Basic and Clinical Oncology, 15, 397-416.
64. Chan, S. Y., Gordon, A. N., Coleman, R. E., et al. (2003) A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunology, Immunotherapy 52, 243-248.
65. Gillespie, A. M., Broadhead, T. J., Chan, S. Y., et al. (2000) Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMOl-calicheamicin) in patients with epithelial ovarian cancer. Annals of Oncology, 11, 735-741.
66. Ojima, I., Geng, X., Wu, X., et al. (2002) Tumor-specific novel taxoid-monoclonal antibody conjugates. Journal of Medicinal Chemistry, 45, 5620-5623.
67. Kigawa, J., Minagawa, Y., Kanamori, Y., et al. (1998) Glutathione concentration may be a useful predictor of antibody-cytotoxic agent conjugates for cancer therapy response to secondline chemotherapy in patients with ovarian cancer. Cancer, 82, 697-702.
68. Ojima, I. (2004) Use of fluorine in the medicinal chemistry and chemical biology of bioactive compounds-A case study on fluorinated taxane anticancer agents. Chem Bio Chem, 5, 628-635.
69. Ojima, I. (2008) Guided molecular missiles for tumor-targeting chemotherapy: case studies using the 2nd-generation taxoids as warheads. Accounts of Chemical Research 41, 108-119.